Sort   by:  
 Page size 
ProteomicsFMNL2/SRC-mediated androgen receptor translocation into the nucleus promotes enzalutamide resistance of prostate cancer
Enzalutamide, a second-generation androgen receptor (AR) antagonist, has represented the association with improved overall survival in men with prostate cancer (PCa). However, PCa patients receiving enzalutamide will eventually develop resistance through various mechanisms without effective regimens...
ORGANISM(S): Homo sapiens (Human) 
2025-01-13 | PXD059539 | Pride
Ar Fmnl2 Prostate cancer，enzalutamide resistance 
TranscriptomicsExpression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells
Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We performed global gene expression analysis by cDNA microarrays to identify genes responsible for enzalut...
ORGANISM(S): Homo sapiens 
2015-04-09 | E-GEOD-64143 | biostudies-arrayexpress
TranscriptomicsRNA-Seq analysis of prostate tumors with or without androgen receptor splice variant
Background. Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor protein which lacks the ligand-binding domain, the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of AR-V7 in circ...
ORGANISM(S): Homo sapiens 
2014-09-03 | E-GEOD-56701 | biostudies-arrayexpress
GenomicsEnzalutamide resistance in prostate cancer cells
Enzalutamide resistance in prostate cancer cells
PRJNA633640 | ENA
ProteomicsProteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
Enzalutamide (ENZA) is a frequently used therapy in metastatic castration-resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to...
ORGANISM(S): Homo sapiens (Human) 
2022-06-24 | PXD031847 | Pride
Prostate cancer Secondary resistance Enzalutamide 
GenomicsEnzalutamide resistance in C42-B prostate cancer cells
Enzalutamide resistance in C42-B prostate cancer cells
PRJNA634557 | ENA
GenomicsIdentification of Genes Promoting Resistance to Enzalutamide
Identification of Genes Promoting Resistance to Enzalutamide
PRJNA659253 | ENA
TranscriptomicsAcquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in Castration-Resistant Prostate Cancer
Illumina gene array analyses of prostate cancer cell lines that had acquired resistance to Enzalutamide (MDV3100). mRNA analyses of four cell lines (CWR-R1, LAPC-4, LNCaP, and VCAP) cells that were either untreated, treated for 48hrs with Enz (short-term), or continuously grown in Enzalutamide for >...
ORGANISM(S): Homo sapiens 
2016-02-24 | E-GEOD-78201 | biostudies-arrayexpress
GenomicsTargeting DNMTs to overcome enzalutamide resistance in prostate cancer
Targeting DNMTs to overcome enzalutamide resistance in prostate cancer
PRJNA763500 | ENA
GenomicsPLK1-mediated PDCD4 degradation confers resistance to enzalutamide in prostate cancer
PLK1-mediated PDCD4 degradation confers resistance to enzalutamide in prostate cancer
PRJNA1183556 | ENA
Sort   by:  
 Page size